AstraZeneca's Tezspire Scores Big in Oesophagus Disease Trial

AstraZeneca's asthma drug Tezspire has shown promising results in a late-stage trial for oesophagus disease, giving the company a much-needed boost after a string of setbacks. The study found that Tezspire significantly reduced inflammation and eased swallowing difficulties in patients with eosinophilic esophagitis, a condition affecting over 470,000 people in the United States.

The drug, developed by AstraZeneca in collaboration with Amgen, is already approved for use as an add-on treatment for severe asthma. It works by blocking a protein that triggers inflammation in conditions driven by eosinophils, a type of white blood cell. Tezspire generated $1.13 billion in sales for AstraZeneca in 2025.

However, investors remain cautious as the company grapples with patent expiries and geopolitical challenges. AstraZeneca's CEO Pascal Soriot is steering the company towards its target of $80 billion in annual sales by 2030, counting on up to 20 new drug launches.